ABSTRACT Objective: To estimate the prevalence and incidence of type 2 diabetes using a national pharmacy claims database.
INTRODUCTION
Diabetes mellitus is a leading cause of death globally, causing almost 4 million deaths in 2010. 1 Morbidity arising from the disease is also substantial; the Global Burden of Disease study estimated a 30% increase in disability-adjusted life years for diabetes between 1990 and 2010 due to increasing prevalence of the disease and increased longevity of those living with diabetes. 2 To reduce diabetes-related mortality and morbidity, access to appropriate healthcare services for people with diabetes is a necessity. For this to be successful, up-to-date population level estimates of disease burden are required to rationally plan and deliver the required health services.
The Institute of Public Health (IPH) estimates and forecasts for the prevalence of diabetes (combined type 1 and type 2) are often cited and are a valuable resource. 3 However, the most recent estimates from the IPH are based on a cross-sectional survey of adults in the Survey of Lifestyle, Attitudes and Nutrition (SLAN) which dates back to 2007. 3 4 Other estimates of diabetes prevalence come from The Irish Longitudinal Study of Ageing (TILDA), which is limited to those over 50 years, 5 6 the Mitchelstown cohort which was limited to adults aged 50-69 years
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▸ Many estimates for the burden of diabetes come from cohort studies and surveys, which are often not population based. There are very few estimates of incidence of diabetes globally. ▸ We used a national administrative pharmacy claims database to calculate prevalence and incidence of type 2 diabetes. This method captures all treated cases of diabetes and thus avoids problems with sampling and generalizing to whole populations that arise from cohort and survey methods. ▸ Understanding the true burden of disease in our society is essential for the planning of health services, which in turn help achieve optimal outcomes in terms of diabetes-related morbidity and mortality. Using pharmacy claims data is a straightforward method of achieving up to date estimates.
in one rural area in the South of Ireland 7 and the Central Statistics Office (CSO) Quarterly National Household Survey (QNHS) from 2010. 8 These estimates are based on a variety of self-reported doctor diagnosis; self-reported diabetes medication usage; or a combination of self-report and HbA1c data; and all are limited to adult populations. Furthermore, there is a scarcity of data available on the incidence of diabetes in Ireland. 9 In this study, we used national pharmacy claims data to estimate the prevalence and incidence of type 2 diabetes. These data provide an objective measure of treated diabetes in the total population to complement existing sample-based estimates.
METHODS

Health system
In Ireland, access to and reimbursement for diabetes medicines occur via two publicly funded community drug schemes. The first is the General Medical Services (GMS) scheme; the main public health insurance program providing primary and secondary healthcare free at the point of access to ∼40% of the Irish population on a means-tested basis. 10 Medicines are included under this scheme but are subject to a copayment (€2.50 currently). The second drug scheme is the longterm illness (LTI) scheme. The LTI provides free access to condition-related medicines for individuals diagnosed with any of 16 chronic illnesses including diabetes. LTI coverage is independent of income.
Data
Pharmacists dispensing medicines to all patients (adults and children) on the GMS and the LTI scheme are reimbursed by the government via the Health Service Executive-Primary Care Reimbursement Service (HSE-PCRS). We used dispensing data from the HSE-PCRS database from July 2011 to December 2012. Data were available for the drug dispensed (classified by WHO Anatomical Therapeutic Chemical (WHO ATC) code), date dispensed, quantity and strength, in addition to patient age and sex.
Population denominator data for the year 2012 were population estimates derived by the CSO based on the 2011 census.
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Definitions Type 2 diabetes was classified as using any strength or quantity of an oral hypoglycemic agent (WHO ATC A10B), irrespective of age or insulin use. The different agents included in this study, stratified by age and sex, are given in table 1.
Calculation of incidence and prevalence
To estimate the prevalence of type 2 diabetes, we used dispensing data for 2012. We counted the number of people in the database who met our definition of type 2 diabetes and used this as the numerator. The total population count published by the CSO was the denominator.
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To establish the annual incidence for type 2 diabetes in 2012, we used data from July 2011 to December 2012. An individual's first occurrence in 2012 meeting the definition of type 2 diabetes was referred to as the index date. A 6 month look-back period was used to rule out prior use before the index date. If no prior use of an oral hypoglycemic agent occurred in the look-back period, then the individual was an incident user of oral hypoglycemic medicines and thus an incident case. This count was used as the numerator, while the denominator was the total population count published by the CSO minus the number of prevalent of cases. 11 We carried out subgroup analyses by age group (<15 years, ≥15 years, 15-24 years, 25-34 years, 35-44 years, 45-54 years, 55-64 years, 65-69 years and >70+ years) and sex.
RESULTS
In 2012, 1 655 013 people accessed a prescription on the GMS scheme and were available in our data set. The mean figure 1) .
DISCUSSION
This cross-sectional study estimated the prevalence and incidence of type 2 diabetes using population level data from a national pharmacy claims database. The overall prevalence in the adult population was 3.16%. The incidence of type 2 diabetes was 6 cases per 1000 adult people in 2012.
Existing prevalence estimates pertaining to the general adult population range from 3% in the Quarterly National Household survey to 3.5% in those aged ≥18 years using SLAN survey data. 4 8 Our estimate of 3.16% is thus comparable to previous figures. In addition, our age stratified estimates for people aged ≥50 years are similar to those based on TILDA using self-report of doctor diagnosis and HbA1c measures. 5 6 However, our estimates may underestimate the true burden of diabetes given that we have excluded type 1 diabetes and we also could not account for lifestyletreated diabetes or undiagnosed diabetes. Despite this, the true prevalence rate of diabetes in Ireland is likely lower than that in the USA which was recently estimated at 8.3% in the adult population. 12 In England, diagnosed diabetes in the population aged ≥16 years is estimated at 5.6% from Health Survey for England data. 13 The only other estimate of incidence of type 2 diabetes in Ireland is 2 cases per 1000, in contrast to the 6 cases per 1000 we found in this study. 9 An American study using the National Health Interview Survey found an incidence rate of 7.1/1,000 people aged ≥20 years in 2012, indicating that Irish incidence rates are below those in North America. 12 A recent Danish study calculated incidence rates for every year of age.
14 While it is difficult to compare single age estimates with estimates for age categories, our estimates appear comparable to those in the Danish study, albeit somewhat higher in the older age groups. 14 Making international comparisons is helpful to aid in understanding the plausibility of our estimates, however differences do exist between populations for demographic and methodological reasons. 15 The study is limited by lack of information on undiagnosed diabetes and lifestyle-treated diabetes. Other data sources, for example the Mitchelstown Cohort and SLAN survey, provide information on undiagnosed diabetes, which can be used in tandem with our results. 4 7 Unpublished data from the Mitchelstown Cohort study of over 2000 adults aged 50-69 years reveal that ∼7% of those with self-reported diabetes are treated with diet only. 16 Although these data are not nationally representative, they provide some context on the magnitude of underestimation. Furthermore, we relied on diagnosed individuals adhering to their treatment regimens, their dispensed medications thus appearing in the pharmacy claims database. We did not anticipate non-adherence to be a major problem given that medicines are free on the LTI scheme and subject to a small copayment on the GMS scheme (€0.50 per item in 2012). 17 The study is strengthened by the objective and reliable nature of the data. 18 Additionally, because diabetes medicines are generally provided only through the GMS and LTI drug schemes, data on those with diagnosed and treated diabetes should be nationally complete in this database offering population level data for all ages, including children, in contrast to previous surveys and cohort studies which are limited to adults. Unfortunately, the database does not have access to diagnosis codes, thus we made the assumption that all oral hypoglycemic agents were being used to treat diabetes. A notable exception is the use of metformin for polycystic ovarian syndrome (PCOS). However, as PCOS effects only a small proportion of women of reproductive age, ∼8%, and only some of these will be treated, any effect on our estimates is likely to be small. Further, many women with PCOS will have diabetes, and we will have intended to include them in our estimates. 19 Metformin is also used in pre-diabetes, which due to lack of diagnosis codes, we have not been able to separate from our estimates. We know from our prior research that the prevalence of pre-diabetes in those aged ≥45 years is 20%. 20 From the most recent audit of diabetes management in General Practice, we know that ∼90% of those with pre-diabetes are treated with dietary intervention (unpublished). 21 Thus, any bias contributed to our results from including those with metformin-treated prediabetes is likely to be inconsequential.
Our study has demonstrated the utility of routinely collected administrative claims data in calculating measures of disease burden, including incidence. The method is straightforward, and while we used data from 2012 for this study, more current data would allow estimating disease burden for the most recently completed calendar year along with establishing longitudinal trends. This approach affords advantages in real-time monitoring of disease burden and thus presents a key resource for evaluating public health interventions to reduce the prevalence and incidence of type 2 diabetes, thus informing health policy and health service planning. To address acknowledged weaknesses in using these data, estimates for prevalence and incidence should be considered in combination with crosssectional and cohort study results to account for undiagnosed and lifestyle-treated cases.
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